Treatment of Gambiense Human African Trypanosomiasis in Children Aged Under 6 Years or Body Weight Under 20 kg with Normal CSF Findings

This first-line protocol covers gambiense human African trypanosomiasis (HAT) in a specific paediatric sub-population: patients aged under 6 years or with body weight under 20 kg whose cerebrospinal fluid findings indicate no central nervous system involvement.

Clinical scenario

Confirmed gambiense human African trypanosomiasis
Age < 6 years or body weight < 20 kg
CSF white blood cell count ≤ 5/µL and no trypanosomes in CSF

Treatment approach

Pentamidine is the first-choice treatment for this patient profile. The complete administration schedule, dosage, and monitoring requirements are detailed in the full structured protocol.

Full regimen, dosage, and clinical guidance available below →

Instant Access to Structured Evidence-Based Regimens

References

Pentamidine is the first-choice treatment in gambiense HAT patients aged < 6 years or body weight < 20 kg presenting with ≤ 5 WBC/µL and no trypanosomes in CSF.

View source ↗